Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia

6 Jan 2023

Abstract excerpt

Minimal/measurable residual disease (MRD) evaluation has resulted in a fundamental instrument to guide patient management in acute lymphoblastic leukemia (ALL). From a methodological standpoint, MRD is defined as any approach aimed at detecting and possibly quantifying residual neoplastic cells beyond the sensitivity level of cytomorphology. The molecular methods to study MRD in ALL are polymerase chain reaction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36672325
DOI: 10.3390/cancers15020374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic LeukemiaPMID 36672325Read ↗

An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read ↗

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical AdvancesSemantic proximity Read ↗

Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.Semantic proximity Read ↗

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?Semantic proximity Read ↗

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesSemantic proximity Read ↗

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCRSemantic proximity Read ↗

Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia – a proof-of- concept studySemantic proximity Read ↗

Minimal Residual Disease Using Liquid Biopsies in Hematological MalignanciesSemantic proximity Read ↗

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patientSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.